News Releases

Month Year

Email Alerts

May 12, 2006

Insmed Incorporated to Present at the Rodman & Renshaw 3rd Annual Healthcare Conference
May 8, 2006

Insmed Incorporated Reports Financial Results for the First Quarter Ended March 31, 2006
May 2, 2006

Insmed Inc. to Webcast 2006 First Quarter Financial Results Conference Call, Monday May 8, 2006 at 4:30 p.m. (ET)
May 1, 2006

IPLEX(TM) Demonstrates Significant, Dose-Dependent Increases in Growth Rate
Apr 26, 2006

Insmed Announces Podium Presentation at the Pediatric Academic Societies' 2006 Annual Meeting
Apr 25, 2006

NORD Honors Insmed for Role in Developing Treatments for Rare Diseases
Mar 22, 2006

Insmed Announces Additional Information in Compliance with NASDAQ Rules
Mar 15, 2006

Insmed Completes $46 Million Public Offering; Underwriters Exercise In Full Option to Purchase Additional Shares
Mar 10, 2006

Insmed Prices $40 Million Equity Offering
Mar 6, 2006

Insmed Incorporated Announces Proposed Public Offering of Common Stock
Mar 2, 2006

Insmed Incorporated Reports Financial Results for the Fourth Quarter and Twelve-Months of 2005
Feb 23, 2006

Insmed to Announce 2005 Fourth Quarter and Year End Financial Results; Thursday, March 2
Feb 3, 2006

Insmed Incorporated Files Shelf Registration Statement
Jan 4, 2006

U. of Rochester Initiates Phase 2 Clinical Trial of Insmed's iPlex for the Treatment of Myotonic Muscular Dystrophy; Trial Funded by NIH and MDA Grants
Dec 12, 2005

FDA Approves Insmed's Orphan Drug, IPLEX, for the Treatment of Severe Primary IGF-1 Deficiency; The First Once-Daily Therapy for the Treatment of Severe Primary IFG-1 Deficiency
Dec 8, 2005

Insmed Responds to Complaint Filed by Tercica
Nov 28, 2005

Insmed to Present at the Lazard Capital Markets Life Sciences Conference
Nov 5, 2005

Insmed Incorporated Reports Financial Results for the Third Quarter and First Nine Months of 2005
Nov 2, 2005

Insmed to Present at the Rodman and Renshaw 7th Annual Healthcare Conference
Nov 1, 2005

Insmed to Release Third Quarter Financial Results; Thursday, November 3
Oct 25, 2005

Insmed Receives European Orphan Drug Designation for SomatoKine for the Treatment of Extreme Insulin Resistance; Company to Initiate Clinial Trial in Type A Insulin Resistance
Oct 25, 2005

FDA to Review Insmed's Complete Response to Approvable Letter for iPlex
Oct 24, 2005

Insmed to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
Oct 18, 2005

Insmed to Present at the BIO Investor Forum Conference
Oct 17, 2005

Insmed Submits Response to FDA Approvable Letter for iPlex

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer